Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Panitumumab+ TAS-102 · 1 trial · 1 indication
DLT was evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia for more than 7 days under maximum supportive therapy; 2. Febrile neutropenia; 3. Platelet counts decreased of Grade 3 requiring platelet transfusion or blood platelet decreased of Grade 4; 4. If Course 2 was not initiated within 14 days due to AE related to the protocol treatment; 5. Grade 3 or higher non-hematologic toxicity that was considered clinically significant, except the following cases, Grade 3 gastrointestinal symptoms that could be controlled with supportive therapy (eg, appropriate use of antiemetics, antidiarrheals), and Grade 3 or higher electrolyte abnormalities that were not deemed clinically significant.
PFS rate at 6 months was defined as the crude rate of surviving participants who survived or were not determined as progressive at 6 months from the day of enrollment. Although the subjects who had no imaging data on progression at 6 months after enrollment or the subjects who had lost to follow-up were included in the denominator, these subjects were not handled as progression-free. Progression included both progression disease (PD) based on diagnostic imaging assessed according to response evaluation criteria in solid tumors (RECIST) ver 1.1 and primary disease progression that cannot be confirmed by diagnostic imaging (clinical progression). PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
| Arm | Type | Description |
|---|---|---|
| panitumumab + TAS-102 combination therapy | EXPERIMENTAL | Panitumumab 6 mg/kg every 2 weeks, plus TAS-102 35 mg/m² given orally twice a day in 5 days followed by a 2-day rest period for 2-week cycle, and then a 14-day rest period (28 days per 1 course). |
| Name | Type | Description |
|---|---|---|
| Panitumumab + TAS-102 | DRUG | panitumumab + TAS-102 combination therapy |
Inclusion Criteria: 1. Investigator and subinvestigator judge a candidate is understand clinical trial and comply this protocol. 2. Participants who have given written consent to take part in the study after detailed explanation of the study prior to enrollment 3. Aged ≥20 to \<75 years at the time...
Top 20 of 77 competitors
Panitumumab + TAS-102 is an investigational combination being studied for the treatment of colorectal cancer. It combines panitumumab, a monoclonal antibody, with TAS-102, a small molecule. The combination is being evaluated in a Phase 1 clinical trial to assess its safety and efficacy in patients with colorectal cancer.
Panitumumab + TAS-102 is being developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. The company is conducting clinical research on this combination for colorectal cancer, with a completed Phase 1 trial in Japan.
Panitumumab + TAS-102 is in Phase 1 clinical development. The Phase 1 trial, which has been completed, was designed to evaluate the safety and efficacy of the combination in patients with colorectal cancer. The drug is investigational and not yet approved for any use.
Panitumumab + TAS-102 has one completed clinical trial, identified as NCT02613221. This Phase 1 study, titled 'A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer,' enrolled 56 participants in Japan and included patients aged 20 years and older.
Panitumumab + TAS-102 is a combination regimen that includes TAS-102, a small molecule, plus panitumumab, a monoclonal antibody. It is not the same as TAS-102 alone, as the combination adds panitumumab to the treatment. The combination is being studied for colorectal cancer.